# The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease

> **NCT06819514** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Guangzhou Jiayin Biotech Ltd** · enrollment: 16 (estimated)

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** EXG110 Injection

## Key facts

- **NCT ID:** NCT06819514
- **Lead sponsor:** Guangzhou Jiayin Biotech Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03-01
- **Primary completion:** 2028-03-15
- **Final completion:** 2028-03-15
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06819514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06819514, "The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06819514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*